Job vacancy in Mylan laboratories campus drive on 3rd may 2024 for B pharmacy fresher for production/ QA
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer’s off-patent medicine division, to form Viatris.[1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK[2] and a “Global Center” in Canonsburg, Pennsylvania, US.
In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan went public on the OTC market in February 1973. It was listed on the NASDAQ, and its shares were a component of the NASDAQ Biotechnology and the S&P 500 indices. The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women’s healthcare.Founded in 1961, the company was first located in an abandoned skating rink in White Sulphur Springs, West Virginia. The facility was moved to Pennsauken, New Jersey in 1962, to Princeton, West Virginia in 1963, and then Morgantown, West Virginia, in 1965, and in 1976 it relocated its corporate headquarters to the Pittsburgh suburb Canonsburg, Pennsylvania. Finally in 2004 it moved to a new office center in nearby Southpointe, a suburban business park located in the Pittsburgh suburb of Cecil Township. Mylan Pharmaceuticals was founded as a drug distributor in 1961 by Milan Puskar and Don Panoz.[11] In 1966, the company began manufacturing penicillin G tablets as well as vitamins and other dietary supplements. Panoz left the company in 1969 and Puskar quit the company in 1973, as it grew and experienced financial difficulties. The board hired Roy McKnight as board chairman, who convinced Puskar to return in 1976. The company discontinued operating as a contract manufacturing organization in 1980 and instead chose to market their products under their own “Mylan-labeled” brand. The company had concerns about the practices of its competitors and the FDA in general, and also with regard to companies seeking to bring generic versions of Maxzide. The company hired private investigators to examine its competitors’ practices, and when it found evidence of corruption, it submitted it to the House Oversight and Investigations Committee, which investigated and found fraud and corruption within the Food and Drug Administration’s generic drugs division and at other generic companies. Two of the companies that had gotten approval to market generic versions of Maxzide, Vitarine Pharmaceutical and Par Pharmaceutical, were targets of the company’s initial investigation and were found to have used Maxzide to obtain their bioequivalence data, leading both companies to withdraw its generic competitor to Mylan’s product.
More about company
Vacancy details –
Department – Production/ QA
Qualification – B pharmacy
Experience – Freshers
Salary – Not disclosed
Similar job’s
Job vacancy in Emcure pharmaceuticals walk-in on 3rd & 4th may 2024
In late July 2019, the company and Pfizer announced that Pfizer would spin off and merge its off-patent medicine division, Upjohn, with Mylan. In November 2019, Mylan & Upjohn announced that the name of the new company would be Viatris. The company continued sales of Mylan’s more than 7,500 products, including biosimilars, generics, brand and over-the-counter remedies, with brands including the Epi-Pen, Viagra, Lipitor and Celebrex. The deal was structured as an all-stock, Reverse Morris Trust transaction. Pfizer shareholders owned 57% of the combined new company and Mylan shareholders owned 43%.
In December 2016, the State attorneys general of 20 states filed a civil complaint accusing the company of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.In October 2017, the company announced the launch of the first FDA-approved generic of Teva’s long-acting Copaxone. Approximately three months later, Credit Suisse analyst Vamil Divan cited IMS Health data which showed that the new generic accounted for 10% of the market.
Important details –
Location – Tamil Nadu
Selection process – The selection will be on the basis of interview
Mode of interview – Face to face
Interview rounds of interview – HR
Walk-in interview details –
Date- 3rd may 2024
Time – 09:00 Am
Venue – The Erode college of pharmacy perundurai main road, Veppampalayam, Vallipurathanpalayam (PO), Erode , Tamilnadu – 638112
For more job related updates joined WhatsApp group
https://chat.whatsapp.com/KCk1lRtEdlJEJYDBTQNc9i